STC1 Induction by PACAP is Mediated Through cAMP and ERK1/2 but not PKA in Cultured Cortical Neurons
Authors:
- 6 October 2011
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 46 (1) , 75-87
Abstract
The neuroprotective actions of PACAP (pituitary adenylate cyclase-activating polypeptide) in vitro and in vivo suggest that activation of its cognate G protein-coupled receptor PAC1 or downstream signaling molecules, and thus activation of PACAP target genes, could be of therapeutic benefit. Here, we show that cultured rat cortical neurons predominantly expressed the PAC1hop and null variants. PACAP receptor activation resulted in the elevation of the two second messengers cAMP and Ca2+ and expression of the putative neuroprotectant stanniocalcin 1 (STC1). PACAP signaling to the STC1 gene proceeded through the extracellular signal-regulated kinases 1 and 2 (ERK1/2), but not through the cAMP-dependent protein kinase (PKA), and was mimicked by the adenylate cyclase activator forskolin. PACAP- and forskolin-mediated activation of ERK1/2 occurred through cAMP, but not PKA. These results suggest that STC1 gene induction proceeds through cAMP and ERK1/2, independently of PKA, the canonical cAMP effector. In contrast, PACAP signaling to the BDNF gene proceeded through PKA, suggesting that two different neuroprotective cAMP pathways co-exist in differentiated cortical neurons. The selective activation of a potentially neuroprotective cAMP-dependent pathway different from the canonical cAMP pathway used in many physiological processes, such as memory storage, has implications for pharmacological activation of neuroprotection in vivo.Keywords
This publication has 104 references indexed in Scilit:
- Stanniocalcin 2 Is a Negative Modulator of Store-Operated Calcium EntryMolecular and Cellular Biology, 2011
- PAC1hop, null and hip receptors mediate differential signaling through cyclic AMP and calcium leading to splice variant-specific gene induction in neural cellsPeptides, 2011
- Pituitary adenylate cyclase‐activating peptide induces long‐lasting neuroprotection through the induction of activity‐dependent signaling via the cyclic AMP response element‐binding protein‐regulated transcription co‐activator 1Journal of Neurochemistry, 2011
- Neuropeptide pituitary adenylate cyclase‐activating polypeptide (PACAP) slows down Alzheimer's disease‐like pathology in amyloid precursor protein‐transgenic miceThe FASEB Journal, 2011
- Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)/PAC1HOP1 Receptor Activation Coordinates Multiple Neurotrophic Signaling PathwaysJournal of Biological Chemistry, 2010
- Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemiaProceedings of the National Academy of Sciences, 2010
- Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptideNeuroscience, 2008
- PACAP‐38 induces neuronal differentiation of human SH‐SY5Y neuroblastoma cells via cAMP‐mediated activation of ERK and p38 MAP kinases1Journal of Neurochemistry, 2007
- Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6Proceedings of the National Academy of Sciences, 2006
- Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cellsBiochemical and Biophysical Research Communications, 1989